VALBIOTIS
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the signature of a research partnership in intestinal microbiota with the MEDIS2 Unit from the Clermont Auvergne University on its active substances TOTUM•070 and TOTUM•448 against dyslipidemia and metabolic liver disease, partly financed by the French National Research Agency. Led by a laboratory shared by the two entities, the MIMETiv project will aim to develop a complete and dynamic human gastrointestinal model integrating the microbiota of the small intestine for the first time. This model will provide exclusive data on the effects and modes of action of Valbiotis' plant-based substances at the intestinal level, in the context of non-drug strategies to combat metabolic and cardiovascular diseases.
Pascal SIRVENT, Director of Discovery, Preclinical and Translational Research, and member of the Board of Directors at Valbiotis states: "In research and development, our public-private partnership strategy is based on collaborations with high scientific added value. The in vitro digestive model project led by the MEDIS Unit is a unique innovation in human digestion research, which we have been following for a long time and to which we are very happy to contribute within this new joint laboratory. As an industrial player, the MIMETiv project represents for us a very promising lever to approach cardiovascular and metabolic diseases from a digestive and intestinal perspective, with a particular focus on the intestinal microbiota. This is an innovative angle, in line with our research and development strategy. At the end of this project, we should obtain exclusive data for our active substances in two of our key indications: dyslipidemia and metabolic liver disease."
Stéphanie BLANQUET-DIOT, Professor and Deputy Director of MEDIS, comments: "This in vitro digestive system is unique in the number of parameters reproduced in relation to in vivo digestion in humans, such as body temperature, pH kinetics in the stomach and small intestine, gastrointestinal transit time, differential gastric emptying between liquids and solid particles, salivary, gastric, biliary and pancreatic secretions, absorption of water and digestive products, progressive anaerobics along the digestive tract and microbiota in small intestine-reproducing compartments."
Dyslipidemia and metabolic liver disease (NAFL, NASH), the respective indications for the active substances TOTUM•070 and TOTUM•448, are highly prevalent diseases, precursors to pathologies that are life-threatening for patients (atherosclerosis, cirrhosis). Their complex pathophysiology includes, among other aspects, alterations in carbohydrate and/or lipid metabolism, digestive abnormalities and disturbances of the intestinal microbiota, all of which the MIMETiv project will be able to approach in humans in an integrated manner. Among the main innovations, MIMETiv should provide access to the microbiota of the small intestine, the major site of digestion and absorption of dietary carbohydrates and lipids in humans. To date, data linking metabolic diseases and gut microbiota have mainly been obtained from stool analysis, which partially reflects the microbiota of the colon (large intestine).
The MIMETiv project: an exclusive tool for R&D on metabolic and cardiovascular diseases
The MIMETiv project, which will benefit from the combined expertise of the MEDIS Unit and Valbiotis, will take place in two stages.
The first will lead to the design of the world's most complete model of the human digestive environment in 2024, based on the long-standing in vitro simulation work of the MEDIS Unit. The work will consist in optimizing the ESIN (Engineered Stomach and Small Intestine) system, developed by MEDIS, by improving its performance and integrating the human microbiota in key compartments of the digestive tract such as the small intestine.
Once validated, this model will constitute a proprietary tool for the evaluation of Valbiotis' plant-based active substances in the human digestive environment. The explorations performed will cover a complete set of R&D objectives for two active substances, TOTUM•070 and TOTUM•448:
- metabolomic analysis, to identify the metabolites of these active substances and to specify their bioavailability in the different gastrointestinal compartments;
- analysis of modes of action, to evaluate their effects on digestion and intestinal absorption of lipids and carbohydrates;
- analysis of the intestinal microbiota, to evaluate their impact on dysbiosis associated with metabolic diseases;
- analysis of hepatic metabolic pathways, thanks to the original coupling of ESINs with liver cells in culture, to assess their possible modulation by Valbiotis' active substances.
The Management Committee of the MIMETiv joint laboratory is composed of 5 members. It is co-led by Stéphanie BLANQUET-DIOT, Deputy Director of MEDIS, in charge of the digestive environment simulation platform, with strong expertise in microbiology and intestinal microbiota, in vitro digestion, digestive physiology and nutrition, and Pascal SIRVENT, Director of Discovery, Preclinical and Translational Research, and member of the Valbiotis Board of Directors. He is responsible for the R&D platform in Riom, with extensive expertise in metabolic diseases and the development of plant-based health products.
About Valbiotis
Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, relying on a multi-target strategy enabled by the use of plant-based terrestrial and marine resources.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit: www.valbiotis.com
Name: Valbiotis
ISIN code: FR0013254851
Ticker symbol: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the Valbiotis Universal Registration Document filed to the French Financial Markets Regulator (AMF) on May 19, 2022 and completed by an amendment on November 8, 2022. This document is available on the Company’s website (www.valbiotis.com).
This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis’ shares or financial securities in any country.
1MIMETiv: Microbiote intestinal et maladies métaboliques chez l’Homme (Intestinal microbiota and metabolic diseases in humans): a unique in vitro digestive system to catalyze the development of innovative nutritional strategies.
LabCom Scientific document.
2The MEDIS Unit (Microbiologie Environnement Digestif et Santé: Microbiology Digestive Environment and Health) is a Joint Research Unit between INRAE (Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement: National Research Institute for Agriculture, Food and the Environment) and UCA (Clermont Auvergne University) created in January 2017.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005500/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tinnitus Research: Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model3.7.2025 12:02:00 CEST | Press release
The novel compound AC102 almost completely reversed tinnitus in a preclinical model after a single dose. At the same time, the damaged connections between the auditory nerve and inner ear sensory cells were restored. These findings were recently published in the prestigious International Journal of Molecular Sciences in a joint study conducted by Erlangen University Hospital and Berlin-based drug developer AudioCure. As there is currently no causal treatment for tinnitus, there is a high medical need. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702168211/en/ In 10-20% of tinnitus cases, the noise in the ear is so severe that it significantly impairs the quality of life of those affected. (Source: AI-generated) In the current study, AC102 was administered to the middle ear of one experimental group after acoustic trauma, while a second group received a placebo. Although both groups initially showed signs of tinnitus, th
H2SITE Secures EIC Accelerator Funding to Deploy a Flagship 1 TPD Ammonia Cracker Using Membrane Reactor Technology at a Port in North-West Europe3.7.2025 08:40:00 CEST | Press release
H2SITE has been awarded the EIC (European Innovation Council) Accelerator program for a project aimed at deploying a first-of-its-kind ammonia cracking unit capable of producing 1 ton of high-purity hydrogen per day. The system is based on H2SITE’s proprietary palladium-based membrane reactor technology, which enables the simultaneous catalytic decomposition of ammonia and selective hydrogen separation within a single unit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702142283/en/ Ammonia Cracker using Membrane Reactor Technology This breakthrough technology offers several compelling advantages over conventional ammonia cracking processes: Lowest Levelized Cost of Hydrogen (LCOH) from ammonia due to high efficiency and integrated operation Reduced energy consumption, operating at significantly lower temperatures (400–450 °C) than traditional cracking methods (typically 600–800 °C) High-purity hydrogen output, compliant
Curve Pay and Thales Join Forces to Securely Transform Digital Wallets on iPhone3.7.2025 08:00:00 CEST | Press release
This collaboration between Curve and Thales provides iOS users with greater control, flexibility, autonomy and digital-security for in-store contactless payments and digital wallets Curve, the ultimate digital wallet, today announced deepening its collaboration with Thales, the global leader in advanced technologies, delivering secure modern payment solutions for financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702696837/en/ Thales D1 Platform to power CURVE PAY (Photo: Thales) This partnership comes on the back of Curve launching Curve Pay on iOS, marking a watershed moment in mobile payments. This partnership is a significant step to reshaping everyday spending, allowing Curve customers to benefit from NFC payment directly in the Curve App for contactless payments in store for all end-users on iOS and Android. Curve Pay is underpinned by Thales’ D1 platform on iOS and Android in Europe which allows
Medimaps Group Launches In Europe TBS Osteo Next-Generation Software For Advanced Bone Microarchitecture Assessment3.7.2025 08:00:00 CEST | Press release
New TBS Osteo Advanced next-generation software enhances fracture risk detection beyond standard of care in osteoporosis, a silent disease affecting over 32 million Europeans1 TBS Osteo Advanced next-generation software to be rolled-out across Europe Broad clinical adoption reinforces TBS Osteo leadership in bone microarchitecture evaluation for fracture risk assessment Subscription-based model offers ongoing services and access to future clinical innovations Medimaps Group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, announces the European launch of its MDR-cleared next-generation TBS Osteo Advanced software. Following the product launch in the United States last month, this next milestone reflects the company's commitment to advancing osteoporosis detection and bone health management worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702082335/en/ Medimaps' TBS Osteo next-generatio
ISDA and Ant International Lead New Industry Report on Use of Tokenised Bank Liabilities for FX Settlement and Cross-Border Payments Under Project Guardian3.7.2025 08:00:00 CEST | Press release
Report builds on shared ledger technology and industry expertise of the co-leads as well as members of the Project Guardian FX workstreamIt includes proposed principles for leveraging tokenised bank liabilities and shared ledgers to drive industry adoption of tokenisation and enable 24/7, real-time FX settlement and lower costs for businesses globally The International Swaps and Derivatives Association (ISDA) and Ant International led the Project Guardian FX industry group to develop a new report for implementing tokenised bank liabilities and shared ledger in cross-border payments and foreign exchange (FX) settlement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702791535/en/ Report on Use of Tokenised Bank Liabilities for Transaction Banking by ISDA and Ant International, under the Monetary Authority of Singapore's (MAS) Project Guardian The joint report is produced under the Monetary Authority of Singapore's (MAS) Pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom